Latest News
Endpoints: Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs
De novo design of antibodies enabled by Joint Atomic Modeling
Endpoints exclusive: Harvard startup raises $26M, strikes three pharma partnerships for AI antibody design
Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design
Harvard spinout Nabla Bio nabs $11M for AI-driven antibody design
Nabla Bio raises $11M for an “end-to-end” antibody design platform
Nabla Bio Closes $11M Seed Financing led by Khosla Ventures and Zetta Venture Partners